UBSG long on 8hResistance at ~13.810 needs to be broken in order to further push towards ~15.870Longby phil_x_cryptoUpdated 1
Roche reversalRoche making higher lows inside a descending broadening wedgem, while showing signs of accumulation with a sell wall at 326.85$. The bullish engulfing candles on Jan 11 and the Marubozu on Feb 4 show that the demand for this asset is high at the previous Peak back in December 2014. The fact that there is also MACD hidden bullish divergence on the daily and the monthly strengthens the argument for a reversal and a break out of this structure in the coming weeks or months.Longby luyestefan0
NOVN Long TradeNovartis showin higher lows or/and a inverse head shoulder, inside a right angled broadening wedge, with a partial decline, while showing hidden bullish divergence on all three oscilators MACD, RSI and Stochastic on the Daily timeframe. Its at the perfect spot for entry a long entry. Target 1: 94$ Target 2: 103$ Target 3: 115$Longby luyestefan0
Roche bullish flag2W 50 MA should be in the pocket. Ready to continue higher. BIOLongby FerdiHodler220
Swiss National Bank (SNBN)It is like holding a risk-free of default US equity market fund denominated in CHF with a total return of 0.3%. It's an interesting business: print money and buy stocks. As at 31 December 2020, the key asset allocation data for the foreign exchange reserves and the Swiss franc bond investment portfolio were as follows: USD 36%, EUR 40%, JPY 8%, GBP 6%. Their last reported 13F filing for Q3 2020 included $127,874,338,000 in managed 13F securities and a top 10 holdings concentration of 24.15%. Swiss National Bank's largest holding is Apple Inc. with shares held of 67,699,096. Equities are managed on a purely passive basis, whereby broad market indices of advanced and emerging economies are replicated. Exchange rate and interest rate risks are managed using derivative instruments such as interest rate swaps, interest rate futures, forward foreign exchange transactions and foreign exchange options. In addition, futures on equity indices are used to manage the equity investments. Longby mgiuliani330
MobilezoneMobilezone Breakout of 4 Year Downtrend after Double Bottom and three rising Valley Pattern! Target 1: 13.04 (0.618 Fibonacci) Target 2: 16.68 ( ATH ) Target 3: 22.54 (1.618 Fibonacci)Longby luyestefan0
Meyer Burger: Ascending triangle forming & Less SalesBearish news on less sales, will the forming ascending triangle hold? by nico14Updated 7
Meyer Burger - Not eatableSwiss Company well established in solar cell technique. Best connections to science Strong buy.Longby FlyerdanUpdated 113
NestleThis stock has fallen out of favor these past few months. Price is trying to stabilize around the EMA's. Planning to go long at the CLOSE today. It's ranging at the moment so it may deflect off the long trend (see arrow), but regardless whether she breaks out or continues ranging, this is a decent entry. Longby SLOPolarBearUpdated 0
3d Printing Breakouts - Four more charts from Ark's $prnt ETF$STMN $RSW $PTX $XONE all high uo on the listby Woodcutter0
RLF - Worth a buy?RLF seemingly had a very volatile few months, which is not unlikely for penny stocks. The recent pullback could offer some decent entry levels for the brave however. Technically we're looking at a sharp gap lower at the end of the year with a subsequent rebound that recovered around 75% of the losses so far. Trading volume and volatility have decreased drastically since and the recent small gap higher on positive momentum looks promising. The 0.30 level seems to form a support level, next resistance is at 0.3375 and then at 0.35 (i.e. the trading level before the new year drop off). Any positions engaged now would require the stock to surpass the resistance by quite a margin to have a worthwhile risk-reward ratio. I will be looking at a small position with a tight SL in the 0.275 area and subsequently raise the bar if the stock moves higher. Buy Limit 0.3050, GTD SL 0.2750 Take Profit 0.3900 Longby SLRKUpdated 221
Rekitt Ben: Time to Watch: Europe Happy Holidays By Sun Storm Invest Research A Profit & Solutions Strategy by Sunstorminvest0
SRAIL looks interesting for new cycle going longAs a swiss citizen I'm searching for interesting patterns in local companies. Because of the long downward route in the past and the bullish 5-wave-reaction in the last weeks, there is a possibility for a new cycle up. Lets see... Longby swissfincap1
Wir lieben Raketenbilder!Wir befinden uns vermutlich in Welle 3 eines Aufwärtsimpulses. Das gelbe Viereck markiert die Kaufzone. Mögliches abfallen bis zur grünen Unterstützungslinie, danach müssten die Triebwerke gezündet werden, ansonsten ein tiefer Fall droht. Stop unterhalb der grünen Unterstützung setzen. Beim direkten, nachhaltigen überwinden des roten Abwärtskanals....kaufen! G. HunkelerLongby geripitscher113
Givaudan. world largest fragrance , flavor producer.. Main flavor producer..From Coca, Pepsi, KFC, Macdonald most fast foods, Maggie Mee, most branded perfumes till potato chip, crab meat etc flavor etcby SteveTan1
SREN.vx bullish scenario:SREN.vx bullish scenario: We have technical figure Channel Down in Swiss company Swiss Reinsurance Company Ltd (SREN.vx) at daily chart. Swiss Reinsurance Company Ltd, commonly known as Swiss Re, is a reinsurance company based in Zurich, Switzerland. It is the world's second-largest reinsurer. Founded in 1863, Swiss Re operates through offices in more than 25 countries. Swiss Re was ranked 118th in Forbes 2000 Global leading companies 2016. It was also ranked 313th in Fortune Global 500 in 2015. The Channel Down has broken through the resistance line at 03/11/2020, if the price holds above this level we can have possible bullish price movement with forecast for the next 13 days towards 73.10 CHF. Our stop loss order should be placed at 62.22 CHF if we decide to enter this position. FUNDAMENTALS - Swiss Re and carmaker Daimler announced a joint automotive and mobility insurance venture on Monday, seeking to tap into a wealth of new data generated by highly automated vehicles to help insurers to calculate risk. by greenforexsig10
SREN.vx bullish scenario:We have technical figure Channel Down in Swiss company Swiss Reinsurance Company Ltd (SREN.vx) at daily chart. Swiss Reinsurance Company Ltd, commonly known as Swiss Re, is a reinsurance company based in Zurich, Switzerland. It is the world's second-largest reinsurer. Founded in 1863, Swiss Re operates through offices in more than 25 countries. Swiss Re was ranked 118th in Forbes 2000 Global leading companies 2016. It was also ranked 313th in Fortune Global 500 in 2015. The Channel Down has broken through the resistance line at 03/11/2020, if the price holds above this level we can have possible bullish price movement with forecast for the next 13 days towards 73.10 CHF. Our stop loss order should be placed at 62.22 CHF if we decide to enter this position. Fundamentals: - Swiss Re and carmaker Daimler announced a joint automotive and mobility insurance venture on Monday, seeking to tap into a wealth of new data generated by highly automated vehicles to help insurers to calculate risk. by legacyFXofficial1
MEDARTIS BUYConfirmation of the expanding wedge reversal with partial rise and break out with confirmation of the reversal structure. Target is the IPO price BIO Longby FerdiHodler1
NOVN.vx bearish scenario:We have technical figure Triangle in Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales. The Triangle has broken through the support line at 16/10/2020, if the price holds below this level we can have possible bearish price movement with forecast for the next 16 days towards 74.78 CHF. Fundamentals: - Swiss drugmaker Novartis grabbed a key European panel’s recommendation for its prospective cholesterol drug Leqvio on Friday, clearing the way for its approval in the next couple of months. Novartis is also counting on approval from U.S. regulators before the end of the year for the drug, also known as inclisiran, which the Basel-based drugmaker bought in a deal last year for nearly $10 billion and predicts will be a top seller.by legacyFXofficial1